Optimal Dose of Neuroleptic in Acute Schizophrenia: A Controlled Study of the Neuroleptic Threshold and Higher Haloperidol Dose

Joseph Patrick McEvoy, Gerard E. Hogarty, Sandra Steingard

Research output: Contribution to journalArticle

323 Citations (Scopus)

Abstract

• After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3.7± 2.3 mg/d) for 2 weeks. Ten responding patients were discharged and unavailable for follow-up or refused subsequent randomization, and one nonresponding patient refused randomization. The remaining 95 responding or nonresponding patients were then randomly assigned, double-blind, to a dosage of haloperidol two to 10 times higher (mean, 11.6 ±4.7 mg/d) or to a continuing NT dosage (mean, 3.4±2.3 mg/d) for another 2 weeks. Of the 58 patients exposed only to NT dosages of haloperidol, 72% clinically recovered within the 5-week trial. Higher dosages given to 47 patients did not lead to greater improvement in measures of psychosis, but did produce slightly greater declines in measures of hostility. Higher dosages did regularly lead to significant increases in distressing extrapyramidal side effects.

Original languageEnglish (US)
Pages (from-to)739-745
Number of pages7
JournalArchives of General Psychiatry
Volume48
Issue number8
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Haloperidol
Antipsychotic Agents
Schizophrenia
Random Allocation
Psychotic Disorders
Hostility
Controlled
Dose
Research

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Optimal Dose of Neuroleptic in Acute Schizophrenia : A Controlled Study of the Neuroleptic Threshold and Higher Haloperidol Dose. / McEvoy, Joseph Patrick; Hogarty, Gerard E.; Steingard, Sandra.

In: Archives of General Psychiatry, Vol. 48, No. 8, 01.01.1991, p. 739-745.

Research output: Contribution to journalArticle

@article{9ef296b965b043448f2348f82da3c762,
title = "Optimal Dose of Neuroleptic in Acute Schizophrenia: A Controlled Study of the Neuroleptic Threshold and Higher Haloperidol Dose",
abstract = "• After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3.7± 2.3 mg/d) for 2 weeks. Ten responding patients were discharged and unavailable for follow-up or refused subsequent randomization, and one nonresponding patient refused randomization. The remaining 95 responding or nonresponding patients were then randomly assigned, double-blind, to a dosage of haloperidol two to 10 times higher (mean, 11.6 ±4.7 mg/d) or to a continuing NT dosage (mean, 3.4±2.3 mg/d) for another 2 weeks. Of the 58 patients exposed only to NT dosages of haloperidol, 72{\%} clinically recovered within the 5-week trial. Higher dosages given to 47 patients did not lead to greater improvement in measures of psychosis, but did produce slightly greater declines in measures of hostility. Higher dosages did regularly lead to significant increases in distressing extrapyramidal side effects.",
author = "McEvoy, {Joseph Patrick} and Hogarty, {Gerard E.} and Sandra Steingard",
year = "1991",
month = "1",
day = "1",
doi = "10.1001/archpsyc.1991.01810320063009",
language = "English (US)",
volume = "48",
pages = "739--745",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Optimal Dose of Neuroleptic in Acute Schizophrenia

T2 - A Controlled Study of the Neuroleptic Threshold and Higher Haloperidol Dose

AU - McEvoy, Joseph Patrick

AU - Hogarty, Gerard E.

AU - Steingard, Sandra

PY - 1991/1/1

Y1 - 1991/1/1

N2 - • After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3.7± 2.3 mg/d) for 2 weeks. Ten responding patients were discharged and unavailable for follow-up or refused subsequent randomization, and one nonresponding patient refused randomization. The remaining 95 responding or nonresponding patients were then randomly assigned, double-blind, to a dosage of haloperidol two to 10 times higher (mean, 11.6 ±4.7 mg/d) or to a continuing NT dosage (mean, 3.4±2.3 mg/d) for another 2 weeks. Of the 58 patients exposed only to NT dosages of haloperidol, 72% clinically recovered within the 5-week trial. Higher dosages given to 47 patients did not lead to greater improvement in measures of psychosis, but did produce slightly greater declines in measures of hostility. Higher dosages did regularly lead to significant increases in distressing extrapyramidal side effects.

AB - • After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3.7± 2.3 mg/d) for 2 weeks. Ten responding patients were discharged and unavailable for follow-up or refused subsequent randomization, and one nonresponding patient refused randomization. The remaining 95 responding or nonresponding patients were then randomly assigned, double-blind, to a dosage of haloperidol two to 10 times higher (mean, 11.6 ±4.7 mg/d) or to a continuing NT dosage (mean, 3.4±2.3 mg/d) for another 2 weeks. Of the 58 patients exposed only to NT dosages of haloperidol, 72% clinically recovered within the 5-week trial. Higher dosages given to 47 patients did not lead to greater improvement in measures of psychosis, but did produce slightly greater declines in measures of hostility. Higher dosages did regularly lead to significant increases in distressing extrapyramidal side effects.

UR - http://www.scopus.com/inward/record.url?scp=0026410773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026410773&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1991.01810320063009

DO - 10.1001/archpsyc.1991.01810320063009

M3 - Article

C2 - 1883257

AN - SCOPUS:0026410773

VL - 48

SP - 739

EP - 745

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 8

ER -